448 related articles for article (PubMed ID: 16959960)
1. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
[TBL] [Abstract][Full Text] [Related]
4. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
5. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
7. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells.
Lim JH; Park JW; Choi KS; Park YB; Kwon TK
Carcinogenesis; 2009 May; 30(5):729-36. PubMed ID: 19037087
[TBL] [Abstract][Full Text] [Related]
8. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells.
Parmer TG; Ward MD; Hait WN
Cell Growth Differ; 1997 Mar; 8(3):327-34. PubMed ID: 9056675
[TBL] [Abstract][Full Text] [Related]
9. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Kim EH; Kim SU; Choi KS
Oncogene; 2005 Jan; 24(5):838-49. PubMed ID: 15531913
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
11. Rottlerin induces pro-apoptotic endoplasmic reticulum stress through the protein kinase C-delta-independent pathway in human colon cancer cells.
Lim JH; Park JW; Kim SH; Choi YH; Choi KS; Kwon TK
Apoptosis; 2008 Nov; 13(11):1378-85. PubMed ID: 18807195
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
13. LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.
Wu M; Huang C; Li X; Li X; Gan K; Chen Q; Tang Y; Tang K; Shen S; Li G
J Cell Physiol; 2008 Jan; 214(1):65-74. PubMed ID: 17541939
[TBL] [Abstract][Full Text] [Related]
14. Rottlerin induces apoptosis of HT29 colon carcinoma cells through NAG-1 upregulation via an ERK and p38 MAPK-dependent and PKC δ-independent mechanism.
Lim JH; Woo SM; Min KJ; Park EJ; Jang JH; Seo BR; Iqbal T; Lee TJ; Kim SH; Choi YH; Kwon TK
Chem Biol Interact; 2012 Apr; 197(1):1-7. PubMed ID: 22410117
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
16. Rottlerin inhibits human T cell responses.
Springael C; Thomas S; Rahmouni S; Vandamme A; Goldman M; Willems F; Vosters O
Biochem Pharmacol; 2007 Feb; 73(4):515-25. PubMed ID: 17141738
[TBL] [Abstract][Full Text] [Related]
17. Rottlerin stimulates metallothionein gene expression but inhibits metal transport in Chinese hamster ovary cells.
Chen JH; Huang CH; Lin LY
Toxicol Appl Pharmacol; 2001 Dec; 177(3):256-63. PubMed ID: 11749125
[TBL] [Abstract][Full Text] [Related]
18. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
19. Integrin signaling and cell spreading alterations by rottlerin treatment of chick limb bud mesenchymal cells.
Choi YA; Kim DK; Kang SS; Sonn JK; Jin EJ
Biochimie; 2009 May; 91(5):624-31. PubMed ID: 19306958
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
